TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ZIPHIUS

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ZIPHIUS

ST13

US500000079366407

Classe

5, 9, 10, 35, 42, 44

Pedido

79366407

Registro

7490625

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

34

Atualização mais recente

03/04/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 9, 10, 35, 42, 44

Data de depósito

03/03/2023

Data de registro

03/09/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

03/09/2024

Última transação

03/04/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

98

Localização do titular

BE

Examinador

TURNER, JASON FITZGERALD

Unidade examinadora

L80

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

ZIPHIUS
ZIPHIUS VACCINES NV

Representantes

Andrea S. Fuelleman Neal, Gerber & Eisenberg LLP

Classificação técnica

Classes Nice

Classe 5Classe 9Classe 10Classe 35Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical and medicinal preparations and substances for the treatment of genetic disorders, infectious diseases, parasitic diseases, and oncology in the field of cystic Fibrosis, chlamydia trachomatis, eppstein barr, herpes zoster, herpes simplex, coronaviruses, malaria, leishmaniasis, and trypanosomiasis; chikungunya, dengue, lymphatic filariasis, rift valley fever, yellow fever, zika, malaria, Japanese encephalitis, West Nile fever, schistosomiasis (bilharziasis), Onchocerciasis (river blindness), plagues, tungiasis, typhus, louse-borne relapsing fever, Leishmaniasis, Sandfly fever (Phlebotomus fever), Crimean Congo haemorrhagic fever, Lyme disease, Relapsing fever (borreliosis), rickettsial diseases, Tick-borne encephalitis, tularaemia, chagas disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), all of the foregoing based on self-amplifying RNA and Lipid based delivery vehicles; vaccines

Classe 9

Downloadable mobile applications and downloadable computer software to enable healthcare professionals and patients to access information on pharmaceutical, medical and vaccine products and services; Downloadable e-commerce software to enable users to perform electronic business transactions via a global computer network; Downloadable computer software to enable professionals to optimize workflow, capture and organize information, place orders and track expenses

Classe 10

Surgical apparatus and instruments for medical use; blood pressure and diabetic diagnostic medical devices

Classe 35

Provision of information and advisory services relating to electronic commerce; provision of customer information on pharmaceutical and medical products through an on-line computer network for advertising purposes

Classe 42

Scientific research for medical purposes

Classe 44

Medical services and healthcare services namely, offered through a network of healthcare providers on a contract basis; provision of medical information; provision of medical information to patients and healthcare professionals concerning pharmaceutical products, vaccines, medical diseases and disorders and related treatments via the Internet; gene therapy and stem cell therapy services; medical and psychological counselling services; medical and pharmaceutical consultation; medical diagnostic testing, monitoring and reporting services; genetic testing for medical purposes

Publicações

Histórico de despachos e eventos da marca no USPTO.

34 publicações encontradas

NREP

NEW REPRESENTATIVE AT IB RECEIVED

26/02/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

13/11/2025

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

08/03/2025

FICS

FINAL DISPOSITION NOTICE SENT TO IB

18/02/2025

FIMP

FINAL DISPOSITION PROCESSED

18/02/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

03/12/2024

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

28/09/2024

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

14/09/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

03/09/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

03/09/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

28/08/2024

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

28/08/2024

GPNX

NOTIFICATION PROCESSED BY IB

01/07/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

18/06/2024

PUBO

PUBLISHED FOR OPPOSITION

18/06/2024

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

11/06/2024

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

11/06/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

29/05/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

16/05/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

15/05/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

14/05/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

14/05/2024

RFNT

REFUSAL PROCESSED BY IB

02/01/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

11/12/2023

RFRR

REFUSAL PROCESSED BY MPU

11/12/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

08/12/2023

CNRT

NON-FINAL ACTION WRITTEN

07/12/2023

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

04/12/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

03/12/2023

CNRT

NON-FINAL ACTION WRITTEN

02/12/2023

DOCK

ASSIGNED TO EXAMINER

02/12/2023

MAFR

APPLICATION FILING RECEIPT MAILED

07/04/2023

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/04/2023

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

30/03/2023

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ZIPHIUS ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.